Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
It is increasingly understood that multiple sclerosis (MS) relapse and progression can occur simultaneously, regardless of phenotype, revealing flaws in the traditional classification of MS and prompting increasing use of a spectrum-based view of the disease. This shift is reflected …
It is increasingly understood that multiple sclerosis (MS) relapse and progression can occur simultaneously, regardless of phenotype, revealing flaws in the traditional classification of MS and prompting increasing use of a spectrum-based view of the disease. This shift is reflected …
Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive, interconnected continuum in which type 2 diabetes, chronic kidney disease, heart failure, and overlapping cardiometabolic risk factors mutually accelerate one another’s progression. In everyday family medicine practice, however, these conditions are often managed in …
Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive, interconnected continuum in which type 2 diabetes, chronic kidney disease, heart failure, and overlapping cardiometabolic risk factors mutually accelerate one another’s progression. In everyday family medicine practice, however, these conditions are often managed in …
Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …